1 Min Read
March 28 (Reuters) - LIDDS AB
* ENTERS INTO RESEARCH AGREEMENT WITH UNIVERSITY OF UPPSALA FOR PRECLINICAL DEVELOPMENT OF DRUGS FOR IMMUNE THERAPY OF CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.